Literature DB >> 27844282

Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.

C Requejo1, J A Ruiz-Ortega2, H Bengoetxea3, A García-Blanco3, E Herrán4,5, A Aristieta2, M Igartua4,5, J L Pedraz4,5, L Ugedo2, R M Hernández4,5, J V Lafuente3,6,7.   

Abstract

The unilateral 6-hydroxydopamine (6-OHDA) lesion of medial forebrain bundle (MFB) in rats affords us to study the advanced stages of Parkinson's disease (PD). Numerous evidences suggest synergic effects when various neurotrophic factors are administered in experimental models of PD. The aim of the present work was to assess the morphological changes along the rostro-caudal axis of caudo-putamen complex and substantia nigra (SN) in the referred model in order to test the suitability of a severe model to evaluate new neurorestorative therapies. Administration of 6-OHDA into MFB in addition to a remarkable depletion of dopamine in the nigrostriatal system induced an increase of glial fibrillary acidic protein (GFAP)-positive cells in SN and an intense immunoreactivity for OX-42, vascular endothelial growth factor (VEGF), and Lycopersycum esculentum agglutinin (LEA) in striatum and SN. Tyrosine hydroxylase (TH) immunostaining revealed a significant decrease of the TH-immunopositive striatal volume in 6-OHDA group from rostral to caudal one. The loss of TH-immunoreactive (TH-ir) neurons and axodendritic network (ADN) was higher in caudal sections. Morphological recovery after the implantation of microspheres loaded with VEGF and glial cell line-derived neurotrophic factor (GDNF) in parkinsonized rats was related to the preservation of the TH-ir cell number and ADN in the caudal region of the SN. In addition, these findings support the neurorestorative role of VEGF+GDNF in the dopaminergic system and the synergistic effect between both factors. On the other hand, a topological distribution of the dopaminergic system was noticeable in the severe model, showing a selective vulnerability to 6-OHDA and recovering after treatment.

Entities:  

Keywords:  6-OHDA; GDNF; Neuroregeneration; Parkinson’s disease; Rostro-caudal gradient; VEGF

Mesh:

Substances:

Year:  2016        PMID: 27844282     DOI: 10.1007/s12035-016-0244-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  64 in total

1.  Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian.

Authors:  C Barcia; V Bautista; A Sánchez-Bahillo; E Fernández-Villalba; B Faucheux; M Poza y Poza; A Fernandez Barreiro; E C Hirsch; M-T Herrero
Journal:  J Neural Transm (Vienna)       Date:  2005-01-24       Impact factor: 3.575

Review 2.  Neurobiology and treatment of Parkinson's disease.

Authors:  Anthony H V Schapira
Journal:  Trends Pharmacol Sci       Date:  2008-11-29       Impact factor: 14.819

3.  The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum versus ventral striatum.

Authors:  E Lynd-Balta; S N Haber
Journal:  Neuroscience       Date:  1994-04       Impact factor: 3.590

Review 4.  Neurotrophic factors for the treatment of Parkinson's disease.

Authors:  Aideen M Sullivan; André Toulouse
Journal:  Cytokine Growth Factor Rev       Date:  2011-06       Impact factor: 7.638

5.  Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF.

Authors:  Ann D Cohen; Jennifer L Tillerson; Amanda D Smith; Timothy Schallert; Michael J Zigmond
Journal:  J Neurochem       Date:  2003-04       Impact factor: 5.372

Review 6.  The 6-hydroxydopamine model: news from the past.

Authors:  Fabio Blandini; Marie-Therese Armentero; Emilia Martignoni
Journal:  Parkinsonism Relat Disord       Date:  2008-07-02       Impact factor: 4.891

7.  Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease.

Authors:  E Garbayo; C N Montero-Menei; E Ansorena; J L Lanciego; M S Aymerich; M J Blanco-Prieto
Journal:  J Control Release       Date:  2008-12-25       Impact factor: 9.776

8.  Subpopulations of proliferating cells of the adult hippocampus respond differently to physiologic neurogenic stimuli.

Authors:  Golo Kronenberg; Katja Reuter; Barbara Steiner; Moritz D Brandt; Sebastian Jessberger; Masahiro Yamaguchi; Gerd Kempermann
Journal:  J Comp Neurol       Date:  2003-12-22       Impact factor: 3.215

9.  Increased CSF biomarkers of angiogenesis in Parkinson disease.

Authors:  Shorena Janelidze; Daniel Lindqvist; Veronica Francardo; Sara Hall; Henrik Zetterberg; Kaj Blennow; Charles H Adler; Thomas G Beach; Geidy E Serrano; Danielle van Westen; Elisabet Londos; M Angela Cenci; Oskar Hansson
Journal:  Neurology       Date:  2015-10-28       Impact factor: 9.910

10.  The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.

Authors:  Asier Aristieta; Garikoitz Azkona; Ainhoa Sagarduy; Cristina Miguelez; José Ángel Ruiz-Ortega; Rosario Sanchez-Pernaute; Luisa Ugedo
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

View more
  2 in total

1.  Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Cepeda; A Sharma; H S Sharma; A Ozkizilcik; R Tian; H Moessler; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

2.  Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; S Bulnes; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.